Company intelligence / Profile preview

OrthogenRx

Doylestown, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

OrthogenRx was a medical device company focused on commercializing FDA-approved viscosupplementation (hyaluronic acid) knee injections for osteoarthritis pain. Its primary products, GenVisc 850 (approved 2015) and TriVisc (approved 2019), demonstrated efficacy in clinical studies and were bioequivalent to reference products previously available outside the US. The company was acquired by Avanos Medical in a $160 million deal, which closed in Q1 2022.

Therapeutic areas: Rheumatology
Modalities: DeviceBiologic
Industry: Therapeutic Medical Devices

Partnerships

Meiji Seika Pharma (Japan)Tedec-Meiji Farma (Spain)

Beyond the preview

Go deeper on OrthogenRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OrthogenRx.

Explore the full profile